PubRank

Aparna A Kamat

Author PubWeight™ 59.17‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008 8.77
2 Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006 6.18
3 Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006 3.58
4 Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006 2.86
5 Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008 2.40
6 Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010 2.19
7 Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010 2.04
8 Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007 1.98
9 Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007 1.90
10 Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006 1.87
11 HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008 1.77
12 Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007 1.68
13 Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011 1.65
14 Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther 2006 1.57
15 EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007 1.57
16 Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007 1.53
17 Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009 1.39
18 Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006 1.38
19 Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006 1.38
20 Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007 1.34
21 Relaxin promotes prostate cancer progression. Clin Cancer Res 2007 1.34
22 Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008 1.29
23 Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007 1.11
24 Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 2010 1.04
25 Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010 1.04
26 Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008 1.04
27 Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009 1.04
28 Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2005 1.01
29 Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res 2012 0.94
30 Endocrine effects of relaxin overexpression in mice. Endocrinology 2005 0.89
31 Genetic targeting of relaxin and insl3 signaling in mice. Ann N Y Acad Sci 2005 0.80